Ligand validation:5NZF

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 5NZF designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
5NZF_NAG_A_505	26%	65%	0.194	0.832	0.48	0.85	-	-	0	0	100%	0.9333
5NZF_NAG_B_505	20%	50%	0.235	0.837	0.53	1.36	-	2	0	0	100%	0.9333
5NZF_NAG_D_507	7%	73%	0.379	0.845	0.46	0.57	-	-	0	0	100%	0.9333
5NZF_NAG_B_506	7%	69%	0.345	0.807	0.35	0.85	-	1	0	0	100%	0.9333
5NZF_NAG_C_510	5%	66%	0.416	0.838	0.51	0.8	-	1	0	0	100%	0.9333
5NZF_NAG_A_504	4%	36%	0.318	0.706	0.57	1.89	-	5	0	0	100%	0.9333
5NZF_NAG_C_504	3%	29%	0.358	0.715	0.67	2.14	-	4	0	0	100%	0.9333
5NZF_NAG_D_504	2%	56%	0.401	0.669	0.5	1.18	-	2	0	0	100%	0.9333
5NZF_NAG_B_504	2%	25%	0.384	0.646	0.75	2.27	-	3	0	0	100%	0.9333
5HUG_NAG_A_508	58%	48%	0.098	0.874	0.62	1.37	-	3	0	0	100%	0.9333
4B7Q_NAG_D_511	51%	24%	0.136	0.888	0.54	2.51	-	2	0	0	100%	0.9333
6G02_NAG_A_504	50%	42%	0.107	0.855	0.88	1.37	-	3	0	0	100%	0.9333
4QNP_NAG_A_504	44%	39%	0.166	0.892	0.57	1.77	-	6	1	0	100%	0.9333
6Q23_NAG_C_501	41%	49%	0.179	0.892	0.48	1.48	-	2	0	0	100%	0.9333
3H0C_NAG_A_794	100%	56%	0.021	0.995	0.61	1.08	-	1	0	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3PPS_NAG_B_760	100%	44%	0.028	0.993	0.57	1.57	-	3	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.